drugset / Trial / NCT05987956
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Phase 2/3
Active not recruiting
600 enrolled
Medicine Invention Design, Inc
Omnicure Clinical Research · collabResponsible Party: Individual Sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair · collabUnitedHealthcare · collab
NaSequentialOpen-labelHealth-services research
Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Timeline
- Start
- 2026-03-18
- Primary completion
- 2026-11-18
- Completion
- 2026-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | 600 mg | Oral |